Printer Friendly

MAGAININ APPOINTS CHIEF OPERATING OFFICER

 PLYMOUTH MEETING, Pa., April 16 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced the promotion of Leonard S. Jacob, M.D., Ph.D. to the position of executive vice president and chief operating officer. As chief operating officer, Dr. Jacob will continue to oversee all research and development activities, and, in addition, will be responsible for manufacturing, facilities, patents and scientific administration.
 Dr. Jacob has over 15 years experience in the pharmaceutical business, most recently serving as the company's executive vice president of research and development and as a member of its board of directors. Prior to joining the company in 1989, Dr. Jacob served as worldwide vice president of clinical research and development at SmithKline & French Labs, Inc., a position in which Dr. Jacob had global responsibility for the clinical development of all research drugs.
 "I am pleased to announce the promotion of Dr. Jacob to this newly created position," stated Jay Moorin, president and chief executive officer of Magainin. "We are fortunate to have someone as multi- talented as Dr. Jacob serving as chief operating officer at this crucial stage of our company's development. He has been instrumental in developing the research and development strategy of Magainin over the last four years and has personally guided our lead product candidate, MSI-78, into Phase II clinical trials."
 Dr. Jacob, 44, also serves as a member of the board of directors of the Medical College of Pennsylvania and is a senior editor of Clinical Research Practices and Drug Regulatory Affairs and also serves on the editorial boards of the Journal of Clinical Pharmacology and the International Journal of Experimental and Clinical Pharmacology. Additionally, Dr. Jacob has authored or co-authored several medical textbooks and numerous scientific papers in the anti-infective area.
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of anti-invectives and anti-cancer products based upon compounds isolated from the host defense systems of animals.
 -0- 4/16/93
 /CONTACT: Jay Moorin of Magainin Pharmaceuticals, Inc., 215-941-4020; or Fern Lazar of Dewe Rogerson, 212-688-6840, for Magainin Pharmaceuticals Inc./
 (MAGN)


CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU: PER

TS-LR -- NY010 -- 6619 04/16/93 09:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 16, 1993
Words:363
Previous Article:RIMAGE CORPORATION PURCHASES P.C. BACK-UP TECHNOLOGY, ANTICIPATES IMPROVED FIRST QUARTER EARNINGS
Next Article:DRESSER NAMES PAUL BRYANT VICE PRESIDENT
Topics:


Related Articles
MAGAININ PHARMACEUTICALS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
MAGAININ PHARMACEUTICALS FISCAL 1992 FINANCIAL RESULTS IN LINE WITH EXPECTATIONS
MAGAININ PHARMACEUTICALS FIRST QUARTER FINANCIAL RESULTS IN LINE WITH EXPECTATIONS
MAGAININ PHARMACEUTICALS SECOND QUARTER FINANCIAL RESULTS IN LINE WITH COMPANY EXPECTATIONS
MAGAININ RECEIVES PATENT FOR ANTI-INFECTIVE COMPOUND COMPANY'S SIXTH HOST DEFENSE RELATED PATENT
MAGAININ PHARMACEUTICALS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
Magainin and University of Pennsylvania Report in Cell on Key Peptide In Cystic Fibrosis-Associated Lung Infection

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters